MarketSpotlight

CoronaryArteryDisease

109Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

MarketSpotlight:CoronaryArteryDisease

LastReviewed:

09Jan,2025

209Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

LatestTakeaways

?DatamonitorHealthcareestimatesthatin2024,therewereapproximately237.4millionprevalentcasesofcoronaryarterydiseaseworldwide,andforecaststhatnumbertoincreaseto252.1millionprevalentcasesby2029.

?DatamonitorHealthcareestimatesthatin2024,therewereapproximately5.5millionincidentcasesofacutecoronarysyndromeworldwide,andforecaststhatnumbertoincreaseto5.8millionincidentcasesby2029.

?Theapproveddrugsinthecoronaryarterydiseasespacetargetangiotensinconvertingenzyme,amyloidbeta/amyloid

plaques,adenosinediphosphateP2Y12receptor,calciumchannel,andcoagulationfactorX.Themajorityofmarketeddrugs

areadministeredviatheoralroute,withoneproductbeingavailableinanintravenousformulation.

?Themajorityofindustry-sponsoreddrugsinactiveclinicaldevelopmentforcoronaryarterydiseaseareinPhaseII.

?Therapiesindevelopmentforcoronaryarterydiseasetargetalpha2adrenergicreceptor,endotheliallipase,NLRP3/

inflammasome,reversecholesteroltransport,stemcells/othercelltherapies,andfibroblastgrowthfactorreceptor.Thesedrugsareadministeredviatheintravenous,oral,subcutaneous,andpercutaneouscatheter/injectionroutes.

309Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

DiseaseBackground

Source:

AmericanHeartAssociation(AHA)01/10/2024

AmericanHeartAssociation(AHA)12/05/2022

JournalArticle09/12/2007

(Maddoxetal.)

JournalArticle06/01/2005

(Bertonietal.)

JournalArticle01/15/2009

(Champneyetal.)

JournalArticle02/04/2013

(Deckers)

JournalArticle01/03/2011

(McManusetal.)

JournalArticle07/25/2005

(Roeetal.)

JournalArticle12/01/2008

(Rogersetal.)

JournalArticle09/07/2007

(Yuietal.)

NationalInstitutesofHealth(NIH)12/20/2023

(CoronaryHeartDisease)

NationalInstitutesofHealth(NIH)12/20/2023

(Symptoms)

OnlineBook02/18/2022

(IQWiG)

OnlineBook02/01/2024

(SweisandJivan;Angina)

OnlineBook02/01/2024

(SweisandJivan;CoronaryArteryDisease)

OnlineBook02/01/2024

(SweisandJivan;AcuteCoronarySyndromes)

.au06/01/2022

Coronaryarterydisease(CAD),alsocalledischemicheartdisease,occursduetothenarrowingofcoronaryarteriesthatsupplyoxygen-richbloodtotheheart.Awaxysubstancecalledplaquebuildsupinsidethesearteries,leadingtoatherosclerosis.Plaquebuildsupwithinthecoronaryarterywallsuntiltheflowofoxygen-richbloodtotheheartmuscleislimited.Thisconditionisalsocalledischemia,whichmaybechronicoracute.Inchronicischemia,thecoronaryarterynarrowsovertime,limitingthebloodflowtopartoftheheartmuscle,while

acuteischemiaoccursduetoasuddenruptureofplaqueandformationofabloodclot.Thesebloodclotscancompletelyormostlyblocktheflowofbloodthroughtheartery,leadingtoacutemyocardialischemia,whichfurtherresultsinacutecoronarysyndromes.These

includeunstableangina,non-STsegmentelevationmyocardialinfarction(NSTEMI),andST-segmentelevationMI(STEMI).Iftheoxygen-richbloodflowtotheheartisblockedorreduced,heartattackoranginacanoccur.

Unstableangina(UA):Ofthethreeacutecoronarysyndrome(ACS)subtypes,UAisthemostdifficulttodefineanddiagnose.UAis

angina(chestpain)thatisneworsudden,andmaysignalanimpendingMI.Thisisincontrasttostableangina,whichischestpainthatoccurspredictably,typicallyuponexertion.UApatientsmayhavenormalorabnormalECGs,butdonottestpositiveforbiomarkersofcardiacnecrosis.

ComparedwithMIpatients,UApatientsareoftensignificantlylesshealthyinthattheyaremorelikelytohaveahistoryofcommon

cardiovascularriskfactorssuchastobaccouse,hypertension,anddiabetesmellitus.UApatientstendtohavelowermortalityratesthanMIpatients,butithasbeenarguedthatfavorablemortalityoutcomesdonotnecessarilyindicatebetterlong-termprognosesbecauseUApatientshavesimilarqualityoflifescoresandrehospitalizationratescomparedtoMIpatientsafteroneyear.

DatashowthatUAislesscommonthanMI,butthismaybebecauseUAissometimestreatedinoutpatientsettings,whichprecludesUA

casesfrombeingcaptureduponhospitaladmission,asMIcasesare.Furthermore,asaresultofreviseddefinitions,accordingtowhichanabnormalvalueofthemostsensitivecardiacbiomarkersinapatientwithahighclinicalsuspicionofACSmustbeconsideredtorepresentmyocardialnecrosisandthusMI,manyACSpatientswillbereclassifiedfromUAtoNSTEMI.TheincidenceofNSTEMIwilltherefore

increasesignificantly,andthatofUAwilldecrease.

Myocardialinfarction:MIoccurswhentheheart’sbloodsupplyisinterrupted,usuallybyablockageofthecoronaryartery.STEMIisanMIinwhichtheSTsegmentonapatient’sECGiselevated.ST-segmentelevationisastrongindicationofasuddenlackofbloodgettingtotheheart.Asthenameindicates,NSTEMIisanMIinwhichtheSTsegmentofapatient’sECGisnotelevated;theECGmaybenormalormayhaveotherabnormalitiesindicatingMI.

STEMIandNSTEMIarenotevenlydistributedthroughouttheMIpopulation,andcertaintypesofpatientsaremorepronetooneortheother.StudiesofMIpatientshaveshownSTEMIpatientstobeaboutfiveyearsyoungerthanNSTEMIpatientsonaverage.STEMI

patientsalsotendtobehealthierthanNSTEMIpatients;thatis,theyarelesslikelytohaveahistoryofhypertension,diabetesmellitus,angina,orstroke.InyoungerMIpatients,STEMIismorecommoninmen,butbytheageof80years,itismorecommoninwomen.

409Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

ThemostcommonsymptomofCADisangina.Thisisdefinedasdiscomfortorchestpaincausedbyinsufficientoxygenandbloodflowtotheheartmuscle.Anginagenerallyoccursduringsevereemotionalstressorexertion,astheheartmusclerequiresmorebloodoxygen

thancanbedeliveredbythenarrowedcoronaryartery.Usually,painreduceswithrest.Themainsymptomsofanginaincludepainanddiscomfort,whichcanmanifestasburning,tightness,orsqueezingofthechest.Painalsooccursintheshoulders,neck,jaw,arms,orback.Othersymptomsincludebreathlessness,coldsweating,dizziness,nausea,weakness,light-headedness,orsleepdisturbances.

ThecommonriskfactorsofCADincludehighLDLcholesterol,lowHDLcholesterol,smoking,highbloodpressure,diabetes,lackof

physicalactivity,obesity,lackofsocialcontact,depression,dietaryfactors,andhighlevelsoflipoproteinandC-reactiveprotein(CRP)intheblood.TheriskofCADincreaseswithage,anditismorecommoninmenthaninwomen.FamilyhistoryofearlyCADcanalsobeariskfactorifanycloserelativeshavedevelopedCADbeforetheageof55years.

509Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

Treatment

Source:

AmericanHeartAssociation(AHA)

Biomedtracker

JournalArticle04/01/2011

(Pfliegeretal.)

NationalInstitutesofHealth(NIH)12/20/2023

OnlineBook02/18/2022

(IQWiG)

PrescribingInformation03/02/2015

(Caduet)

PrescribingInformation05/01/2020

(Brilinta)

PrescribingInformation06/01/2011

(Aceon)

UKNationalHealthService(NHS)01/17/2024

ThetreatmentofCADinvolvesheart-healthylifestylechanges,medications,medicalproceduresorsurgery,andcardiacrehabilitation.ThemaingoaloftreatmentmayincluderelievingsymptomsandpreventingCADcomplications,wideningorbypassingthecloggedarteries,

loweringtheriskofformingbloodclots,andreducingriskfactorsforapatientinanefforttodelay,stop,orevenreversetheplaquebuildup.Aphysicianmayrecommendheart-healthylifestylechangessuchascontrollingstress,quittingsmoking,physicalactivity,heart-healthy

eating,maintainingahealthyweight,andgettingasufficientamountofgood-qualitysleep.

Medicalmanagement

PatientswithstableCADrequiremedicaltreatment,withthegoalofpreventingdiseaseprogressionandrecurrentcardiovascularevents.Lipid-lowering(suchasstatins),antihypertensive(suchasbeta-blockers,calciumchannelblockers,andnitrates),andantiplateletagents(suchasaspirinandclopidogrel)arethethreeessentialtypesofmedicaltherapiesforthetreatmentofCAD.Inadditiontostatins,othermedicationssuchasfibrates,nicotinicacid,andezetimibecanalsobeusedtoreducecholesterollevels.Pleasenote,furthercoverageofthesedrugsforthetreatmentofdyslipidemiacanbefoundinDatamonitorHealthcare's

DiseaseAnalysis:Dyslipidemia

.

Antiplatelets:Alsoknownasantiaggregants,theyinhibittheplatelets’functioninthebloodbydelayingthebloodclottingprocess,and

preventtheplateletsfromattachingtothebloodvesselwalls.Aspirin(acetylsalicylicacid)andPlavix(clopidogrel)areapprovedinvariouscountriesforlong-termCADtreatment.Plavixisusuallyusedasanalternativewhenpatientscannottolerateaspirin.In2020,theUSFoodandDrugAdministration(FDA)approvedaspirinplusBrilinta(ticagrelor)foruseinhigh-riskCADpatientswithnopriorheartattackor

stroke.Brilintaisanoral,reversibleagentthatinhibitsplateletaggregationbyblockingtheadenosinediphosphatereceptor.

Statins:Thesearealsoknownas3-hydroxy-3-methyl-glutaryl-CoA(HMG-CoA)reductaseinhibitors.Statinsareusedtoreducethe

cholesterollevelsintheblood.Thesedrugsaremoreeffectiveinloweringlevelsof“bad”cholesterol,aswellastriglyceridefats.Statins

arealsousedtoincreaselevelsof“good”cholesterol.SomeofthestatinsavailableintheUSareLescol(fluvastatin),Lipitor(atorvastatin),Pravachol(pravastatin),Mevacor(lovastatin),Crestor(rosuvastatincalcium),andZocor(simvastatin).ThesedrugsarerecommendedtopeoplewithCAD,diabetes,peripheralarterydisease,andhighLDLcholesterollevels.Moreover,statinscanalsobeusedbypeoplewhohavehadastroke.

Beta-blockers:Theseslowtheheartrate,therebyloweringthestrainontheheart,andalsolowerbloodpressure.Beta-blockersareparticularlysuitableforindividualswithCADaswellasheartfailureorhighbloodpressure,andcanbeusedforrelievingorpreventingangina(chestpain)symptoms.Themostcommonlyusedbeta-blockersaremetoprololandbisoprolol.

Calciumchannelblockersandnitrates:Thesedrugshelptorelieveorpreventanginasymptomsbywideningthebloodvesselsandloweringtheheartrate.Calciumchannelblockersreducethebloodpressureandalsothestraininthechambersoftheheart.Theyaremostlyusedbyindividualswhocannottakeortoleratebeta-blockers,orwhoarenotgettingsufficientreliefwiththeuseofbeta-blockers.Nitratesarefast-actingdrugswhichcanbeusedintheformofaspraytotreatacuteanginaattacks.

Angiotensin-convertingenzyme(ACE)inhibitorsandangiotensinIIreceptorblockers(ARBs):Thesedrugshelpinreducingbloodpressure.Typically,ACEinhibitorsareusedfirstastheytendtobeeffective,butifthepatientcannottolerateACEinhibitors,ARBsareconsidered.

Medicalproceduresandsurgery

PatientswithCADmayneedamedicalprocedureorsurgery:

609Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

?Percutaneouscoronaryintervention(PCI),alsoknownasangioplasty,isanon-surgicalprocedurewhichisusedtoopenthenarrowedorblockedcoronaryarteries.

?Coronaryarterybypassgrafting(CABG)isasurgicalprocedurethatusesthearteriesorveinsfromotherpartsofthebodytobypassthenarrowedcoronaryarteries.CABGhelpsinimprovingthebloodflowtotheheart,relievingchestpain,andpossiblypreventingaheartattack.

?Coronaryendarterectomyortransmyocardiallaserrevascularizationisusedtotreatsevereanginaassociatedwithcoronaryheartdiseasewhenothertreatmentsdonotworkorappeartoorisky.

Cardiacrehabilitation

PeoplewithCADarerecommendedtoparticipateinacardiacrehabilitationprogram.Thegoaloftheprogramistoincreasephysical

enduranceandlifeexpectancy,andtopreventcomplications.Theprogramusuallyconsistsofacombinationoflearningtomanagethe

conditionanditsriskfactors,physicalexercise,andpsychologicalsupport.Thecardiacrehabilitationprogrammayinvolvespecialistsfromdifferentfields,suchasphysiotherapy,nutritionalsciences,andpsychotherapy.

709Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

Epidemiology

Source:

AustralianBureauofStatistics(ABS)12/15/2023

CentersforDiseaseControlandPrevention(CDC)01/02/2017

DatamonitorHealthcare(DMHC)

JournalArticle01/14/2016

(Krishnanetal.)

JournalArticle09/01/2020

(Oliveiraetal.)

JournalArticle04/03/2006

(Sanietal.)

JournalArticle01/01/2003

(Yasseretal.)

JournalArticle08/23/2021

(Zhaoetal.)

JournalArticle08/25/2020

(Coffeyetal.)

JournalArticle07/01/2017

(Nakamuraetal.)

JournalArticle02/24/2017

(Wangetal.)

JournalArticle06/10/2010

(Yehetal.)

PublicHealthScotland

UKNationalHealthService(NHS)12/04/2018

UnitedNations

DatamonitorHealthcareusedhistoricalprevalencedatatoestimateandforecasttheprevalenceofcoronaryarterydiseaseinpeopleaged20yearsandolderintheUnitedNations(UN)worldregions(World,Africa,Asia,Europe,LatinAmericaandtheCaribbean,Northern

America,andOceania).

DatamonitorHealthcareidentifiedseveralsourcesforestimatesofcoronaryarterydiseaseprevalence,mainlypopulation-basedstudiesandnationalsurveysdescribingdiagnoseddataataregionallevel.Thedataconsistedofself-reportedprevalenceand/orprevalence

determinedbyInternationalClassificationofDiseases(ICD)-10codes.Multiplesourcesusedinthisforecastreportonprevalenceof

ischemicheartdiseaseorcoronaryheartdiseaseinsteadofcoronaryarterydisease.Thesetermsareusedinterchangeablywithcoronaryarterydisease,andsohavebeenincludedasaproxy.

Dataontheincidenceofacutecoronarysyndromearescarce.Therefore,DatamonitorHealthcareincludedstudieswhicheitherreportedacutecoronarysyndromeoracutemyocardialinfarction/unstableangina.Studiesreportingacutecoronarysyndromeincidencewere

basedonICDcodesorEuropeanSocietyofCardiologyguidelinescriteria.Forstudieswhichreportedmyocardialinfarction,diagnostic

criteriawerebasedonECGreportsorwereregistrydatabasedontheICDcodes.Region/country-specificdatawereavailableforAsia,

Europe,NorthernAmerica,andOceania.ForAfricaandtheLatinAmericaandtheCaribbeanregion,theincidenceestimatefromAsiawasappliedasthisregionismostsimilarregardingpopulationdemographicsandsocioeconomicfactors.

Tocalculatethenumberofprevalentandincidentcasesforthetwoindicationsinthe2020–29forecastperiod,DatamonitorHealthcare

multipliedtheproportionsbytheregion-specificpopulationestimatesfromtheUNWorldPopulationProspectsdatabase.TheUNdatabasewaschosenasareliablepopulationdenominator;thedataincludestandardsetsofdemographicindicators.

Includedareestimatedprevalentcasesofcoronaryarterydiseaseinpeopleaged20yearsandover,andestimatedincidentcasesof

acutecoronarysyndromeinpeopleaged20yearsandoverduring2020–29.Evidencesuggeststheseindicationsarerareamongchildrenandyoungadults;therefore,epidemiologicaldataarealsorare.Consequently,childrenandyoungadultswereexcludedfromthisanalysis.

Prevalentcasesofcoronaryarterydisease,2020-29

Year

World

Africa

Asia

Europe

LatinAmerican&theCaribbean

NorthernAmerica

Oceania

2020

225,696,000

31,111,000

145,362,000

24,349,000

7,995,000

15,951,000

928,000

2021

228,634,000

32,004,000

147,154,000

24,348,000

8,113,000

16,075,000

940,000

2022

231,559,000

32,916,000

148,923,000

24,338,000

8,230,000

16,199,000

925,000

2023

234,484,000

33,852,000

150,670,000

24,327,000

8,345,000

16,324,000

965,000

2024

237,424,000

34,822,000

152,395,000

24,319,000

8,458,000

16,452,000

978,000

809Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

Year

World

Africa

Asia

Europe

LatinAmerican&theCaribbean

NorthernAmerica

Oceania

2025

240,390,000

35,830,000

154,100,000

24,318,000

8,568,000

16,583,000

991,000

2026

243,301,000

36,848,000

155,756,000

24,318,000

8,676,000

16,699,000

1,004,000

2027

246,230,000

37,903,000

157,383,000

24,324,000

8,780,000

16,822,000

1,018,000

2028

249,179,000

38,996,000

158,986,000

24,336,000

8,882,000

16,947,000

1,032,000

2029

252,147,000

40,126,000

160,569,000

24,351,000

8,983,000

17,073,000

1,046,000

Note:Totalsmaynotsumduetorounding.

?DatamonitorHealthcareestimatesthatin2024,therewereapproximately237.4millionprevalentcasesofcoronaryarterydiseaseinpeopleaged20yearsandoverworldwide.

?Thisnumberisforecastedtoincreasetoapproximately252.1millionprevalentcasesby2029.

?Asiaisestimatedtohavehadthelargestnumberofprevalentcasesin2024(152.4millioncases),whiletheOceaniaregionisestimatedtohavehadthesmallestnumber(978,000cases).

Trendsinprevalentcasesofcoronaryarterydisease,2020–29

Source:Source:DatamonitorHealthcare;HealthSurveyforEngland,2018;Krishnanetal.,2016;NationalHealthInterviewSurvey,2017;NationalHealthSurveyAustralia,2018;Oliveiraetal.,2020;Sanietal.,2006;Sharafetal.,2003;UnitedNations,201

?Globally,thenumberofprevalentcasesofcoronaryarterydiseaseamongindividualsaged20yearsandoverisexpectedtoincreaseby11.7%between2020and2029.

?Thesetrendsaredrivenbypopulationdemographics,asprevalenceproportionswereheldconstantthroughouttheforecastperiod.

909Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

Prevalentcasesofcoronaryarterydiseaseinselectregions,bygender,2020

Region

Male

Female

Total

Proportionmale

Africa

14,660,000

16,451,000

31,111,000

47.12%

Asia

72,805,000

72,557,000

145,362,000

50.09%

Europe

15,676,000

8,673,000

24,349,000

64.38%

NorthernAmerica

9,834,000

6,117,000

15,951,000

61.65%

Oceania

599,000

329,000

928,000

64.58%

Note:Gender-specificprevalenceproportionsarenotavailablefortheLatinAmericaandtheCaribbeanregion.

?CoronaryarterydiseasehasamalepredominanceinEurope,NorthernAmerica,andOceania.

?DatamonitorHealthcareestimatesthatinAsiaandAfrica,coronaryarterydiseasehasasimilarprevalenceinmenandwomen.

Incidentcasesofacutecoronarysyndrome,2020-29

Year

World

Africa

Asia

Europe

LatinAmerican&theCaribbean

NorthernAmerica

Oceania

2020

5,275,000

518,000

2,485,000

1,240,000

341,000

584,000

107,000

2021

5,330,000

533,000

2,515,000

1,239,000

346,000

589,000

109,000

2022

5,385,000

548,000

2,544,000

1,239,000

351,000

594,000

110,000

2023

5,441,000

564,000

2,573,000

1,238,000

355,000

598,000

112,000

2024

5,497,000

580,000

2,602,000

1,238,000

360,000

603,000

113,000

2025

5,551,000

597,000

2,630,000

1,238,000

365,000

607,000

115,000

2026

5,607,000

614,000

2,658,000

1,238,000

369,000

612,000

116,000

2027

5,662,000

632,000

2,685,000

1,239,000

373,000

616,000

118,000

2028

5,718,000

650,000

2,711,000

1,240,000

378,000

621,000

119,000

2029

5,775,000

669,000

2,738,000

1,240,000

382,000

625,000

121,000

Note:Totalsmaynotsumduetorounding.

?DatamonitorHealthcareestimatesthatin2024,therewereapproximately5.5millionincidentcasesofacutecoronarysyndromeinpeopleaged20yearsandoverworldwide.

?Thisnumberisforecastedtoincreasetoapproximately5.8millionincidentcasesby2029.

?Asiaisestimatedtohavehadthelargestnumberofincidentcasesin2024(2.6millioncases),whiletheOceaniaregionisestimatedtohavehadthesmallestnumber(113,000cases).

?Globally,thenumberofincidentcasesofacutecoronarysyndromeamongindividualsaged20yearsandoverisexpectedtoincreaseby9.6%between2020and2029.

?Thesetrendsaredrivenbypopulationdemographics,asprevalenceproportionswereheldconstantthroughouttheforecastperiod.

Trendsinincidentcasesofacutecoronarysyndrome,2020–29

1009Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

Source:DatamonitorHealthcare;Coffeyatal.,2020;Nakamuraetal.,2017;ScottishHeartDiseaseStatistics,2019;UnitedNations,2019;Wangetal.,2017;Yehatal.,2010

?Globally,thenumberofincidentcasesofacutecoronarysyndromeamongindividualsaged20yearsandoverisexpectedtoincreaseby9.6%between2020and2029.

?Thesetrendsaredrivenbypopulationdemographics,asprevalenceproportionswereheldconstantthroughouttheforecastperiod.

MarketSpotlight

CoronaryArteryDisease

1109Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

MarketedandPipelineDrugs

Drug

LeadCompany

Partner

Indication

Target

Phase

ApprovalDate

?AbbVieInc.

Symplmed

(ABBV)

Coronary

?Angiotensin

Approved

Aceon

Pharmaceuticals

?XOMARoyalty

Artery

ConvertingEnzyme

(Generic

08/2005

LLC

Corporation(XOMA)

Disease

(ACE)

Competition)

Caduet

PfizerInc.

?AstellasPharma,

Inc.(4503:JP)

CoronaryArtery

?CalciumChannel

Approved(Generic

01/2004

Disease

Competition)

Coronary

?Device

Sensation7Fr.IAB

GetingeAB

Artery

Disease

Miscellaneous

Approved

01/2007

BxVELOCITYStent

CardinalHealth,

Inc.

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

05/2000

NexStentCarotidStent

BostonScientific

Corporation

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

10/2006

NCQuantumApexPTCA

DilatationCatheter

BostonScientific

Corporation

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

08/2012

WiseguideGuide

Catheter

BostonScientific

Corporation

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

06/1997

DURASTARRxPTCA

DilatationCatheter

CardinalHealth,

Inc.

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

08/2007

FIRESTARRxPTCA

DilatationCatheter

CardinalHealth,

Inc.

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

08/2007

SprinterOTW

SemicompliantOver-the-

WireBalloonDilatation

Catheter

Medtronicplc

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

06/2004

DriverCoronaryStent

System

Medtronicplc

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

10/2003

Coronary

?Device

Watusi

Johnson&Johnson

Artery

Disease

Miscellaneous

Approved

04/2006

Coronary

?Device

CourierMicrocatheter

Johnson&Johnson

Artery

Disease

Miscellaneous

Approved

05/2006

MarketSpotlight

CoronaryArteryDisease

1209Jan,2025Copyright?2025Citeline,aNorstellacompany(Unauthorizedphotocopyingprohibited)

Drug

LeadCompany

Partner

Indication

Target

Phase

ApprovalDate

ApexDilationCatheters

BostonScientific

Corporation

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

11/2008

Muskie

Teleflex

Incorporated

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

Biosensors

Coronary

?Device

BioFreedom

InternationalGroup

Ltd.

Artery

Disease

Miscellaneous

Approved

04/2022

InquiryAFocusII

Catheter

Abbott

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

11/2004

?OrbusNeich

Diamondback360

MedicalGroup

Coronary

?Device

CoronaryOrbital

Abbott

HoldingsLtd.

Artery

Miscellaneous

Approved

10/2013

AtherectomySystem

(6929)

Disease

TherapyCoolFlexRF

AblationCatheter

Abbott

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

12/2013

Coronary

?Device

EagleEyePlatinum

RoyalPhilips

Artery

Disease

Miscellaneous

Approved

12/2009

KinetixGuidewire

BostonScientific

Corporation

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

08/2008

SprinterLegendRX

Coronary

?Device

SemicompliantBalloon

Medtronicplc

Artery

Miscellaneous

Approved

10/2008

DilatationCatheter

Disease

Minnie

Teleflex

Incorporated

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

01/2009

EverCross.035OTW

PTADilationCatheter

Medtronicplc

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

11/2008

Coronary

?Device

NanoCross

Medtronicplc

Artery

Disease

Miscellaneous

Approved

12/2008

SYNERGY

BioabsorbablePolymer

Stent

BostonScientific

Corporation

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

10/2015

IntegrityCoronaryStent

System

Medtronicplc

CoronaryArtery

Disease

?Device

Miscellaneous

Approved

MarketSpotlight

CoronaryArteryDisease

1309Jan,2025Copyright?2025Citeline,aNorstella